公司资料
Nkarta 股价、新闻与催化剂
- 股票代码:
- NKTX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.43 USD (+4.29%)
收盘价
最后更新: 2026年8月17日
208M USD
市值
股价为何变动
As of Aug 17, 2026, NKTX closed up 4.29% at $2.43. No new same-company headline was identified in the current news window.
公司概览
Allogeneic CAR-NK Company
Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer.
NKX019
NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing.
Ntrust Studies
Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with outpatient dosing and the option for redosing.
未来催化剂
- Initial clinical data from the Ntrust-1 and Ntrust-2 studies of NKX019 at a medical conference in 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。